source
- Biohaven secures up to $795 million partnership with SK Biopharma for global epilepsy drug rightsBiohaven announced a commercial partnership for its late-stage epilepsy program. South Korea-based SK Biopharma has agreed to pay up to $795 million for worldwide rights to the company's Kv7 ion ch…
- Vitruvias Therapeutics shuts down after recalling potentially superpotent thyroid tabletsVitruvias Therapeutics announced it is ceasing operations and has voluntarily recalled a batch of its generic thyroid tablets because the product may be superpotent. The recall covers 3,655 units…